MatthewTimothyHuemanMD ,FACS, FSSO

PubMed

• 180 citations
  Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients
  George E. Peoples, Jennifer M. Gurney, Matthew T. Hueman, Mike M. Woll, Gayle B. Ryan
  Journal of Clinical Oncology. 2005-10-20
• 130 citations
  Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinic...
  George E. Peoples, JP Holmes, Matthew T. Hueman, Elizabeth A. Mittendorf, Asna Amin
  Clinical Cancer Research. 2008-02-01
• 28 citations
  Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity wounds
  Felipe A. Lisboa, Matthew J. Bradley, Matthew T. Hueman, Seth Schobel, Gaucher Beverly J
  Surgery. 2017-04-01

Journal Articles

• Liver Disease: Current Surgical Methods Employed  
  Hueman MT, Ahuja N, Eur J Gastroen Hepat, 1/1/2010

Books/Book Chapters

• Early Diagnosis and Treatment of Cancer Series: Colon Cancer 
  Chapter: Colon Cancer: Surveillance and Follow-up. Chapter 15 
  Hueman MT, Ahuja NEditors: Gearhart S, Ahuja N and Yang S.

Abstracts/Posters

• Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine.
  Clifton GT, Holmes JP, Patel R, Benavides LC, Gates JD, Hueman MT, Mittendorf EA, Ponniah S, Peoples GE, Ann Surg Oncol, 1/1/2009
• Optimal dose and schedule of a HER2/neu peptide (E75) vaccine in disease-free breast cancer patients: results from two phase I/II clinical trials.
  Holmes JP, Patil R, Amin A, Jama YH, McNeill A, Hueman MT, Craig D, Ponniah S, Peoples GE, Breast Cancer Res Treat, 1/1/2008
• Long-term follow-up assessment of a HER2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients.
  Gates JD, Benavides LC, Carmichael MG, Holmes JP, Hueman MT, Mittendorf EA, McLeod DG, Ponniah S, Peoples GE, J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 1/1/2008
• Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Tri...
  Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, von Hofe E, Ponniah S, Peoples GE, J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 1/1/2008
• Immune monitoring of CD4+CD25+FoxP3+ regulatory T cells in a novel HLA Class-II HER2/neu peptide vaccine clinical trial in breast cancer patients.
  Hueman, MT (Primary Presenter), Society of Surgical Oncology's 60th Annual Cancer Symposium, Washington, DC, 1/17/2007
• Comparing CD4+CD25+FoxP3+ regulatory T cell levels with ex vivo immune assays and clinical delayed type hypersensitivity responses in a novel HLA Class II HER2/neu pep...
  Hueman, MT (Primary Presenter), 98th Annual Meeting of the American Association for Cancer Research, Anaheim, CA, 1/16/2007
• Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I clinical trial.
  Patil R, Holmes JP, Amin A, Carmichael M, Jama YH, McNeill A, Hueman MT, Craig D, Ponniah S, Peoples GE, Breast Cancer Res Treat, 1/1/2007
• Clinical results of a phase I trial of a HER2/neu-derived peptide (GP2) vaccine in disease-free, node-negative breast cancer patients.
  Carmichael M, Holmes JP, Mittendorf EA, Amin A, Hueman MT, Ponniah S, Peoples GE, Breast Cancer Res Treat, 1/1/2007
• Assessment of pathologic and immunologic patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine.
  Amin A, Holmes JP, Hueman MT, Khoo S, Storrer CE, Smith AM, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE, Proc Amer Assoc Cancer Res, 1/1/2007
• Comparing CD4+CD25+FoxP3+ regulatory T cell levels with ex vivoimmune assays and clinical delayed type hypersensitivity responses in anovel HLA Class II HER2/neu pepti...
  Hueman MT, Holmes JP, Storrer CE, Jama YH, Smith AM, Khoo S, Stojadinovic A, Ponniah S, Peoples GE, Proc Amer Assoc Cancer Res, 1/1/2007
• Breast cancer patients have different levels of endogenous CD8 T cells capable of recognizing a HER2/neu peptide (E75) used as a cancer vaccine in clinical trials.
  Holmes JP, Amin A, Hueman MT, Khoo S, Storrer CE, Jama YH, Smith AM, Craig D, Stojadinovic A, Ponniah S, Peoples GE, Proc Amer Assoc Cancer Res, 1/1/2007
• Combined clinical trial results of a HER2/neu (E75) vaccine for prevention of recurrence in high-risk breast cancer patients.
  Peoples GE, Khoo S, Dehqanzada ZA, Mittendorf EA, Hueman MT, Gurney JM, Woll MM, Ryan GB, Storrer CE, Harris KA, Jama YH, Smith AM, Shriver CD, Ioannides CG, Ponniah S, Breast Cancer Res Treat, 1/1/2006
• Immunological Monitoring of Regulatory T Cells by Flow Cytometry in a novel HLA Class-II HER2/neu Peptide Vaccine Clinical Trial in Breast Cancer Patients.
  Hueman MT, Khoo S, Storrer CE, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE, J Am Coll Surg, 1/1/2006
• Reduction of Regulatory T cell Levels and Enhanced Anti-tumor Immune Responses in Breast Cancer Patients Receiving a HER2 Peptide (E75) Vaccine.
  Hueman, MT (Primary Presenter), 96th Annual Meeting of the American Association for Cancer Research, Anaheim, CA, 1/18/2005
• Levels of Circulating Regulatory CD4+CD25+ T Cells Decreased in Breast Cancer Patients after Vaccination with a HER2/neu (E75) Peptide.
  Hueman, MT (Primary Presenter), Society of Surgical Oncology's 58thAnnual Cancer Symposium, Atlanta, GA, 1/4/2005
• Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High Risk Breast Cancer Patients.
  Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S, J Clin Oncol, ASCO Annual Meeting Proceedings, 1/1/2005
• Prognostic Significance of HLA-A2 Status In Breast Cancer Patients.
  Dehqanzada Z, Hueman MT, Shriver CD, Ponniah S, Peoples GE, J Clin Oncol, ASCO Annual Meeting Proceedings, 1/1/2005
• Levels of Circulating Regulatory CD4+CD25+ T Cells Decreased in Breast Cancer Patients after Vaccination with a HER2/neu (E75) Peptide.
  Hueman MT, Stojadinovic A, Gurney JM, Dehqanzada Z, Storrer CE, Shriver CD, Ponniah S, Peoples GE, Ann Surg Oncol, 1/1/2005
• Assessing Serum Cytokine Profiles in Breast Cancer Patients Receiving a HER2/neu Vaccine Using Luminex Technology.
  Dehqanzada, ZA, Storrer CE, Hueman MT, Foley R, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE, Ann Surg Oncol, 1/1/2005
• Induction of CD8 T lymphocytes specific for the recognition of a breast cancer associated polymorphism in the HER2/neu protein in a clinical trial with the HER2 E75-pe...
  Mittendorf EA, Storrer CE, Dehqanzada Z, Hueman MT, Foley RJ, Jama Y, Harris KA, Shriver CD, Peoples GE, Ponniah S, Proc Amer Assoc Cancer Res, 1/1/2005
• Reduction of regulatory T cell levels and enhanced antitumor immune responses in breast cancer patients receiving a HER2 peptide (E75) vaccine.
  Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada Z, Foley RJ, Jama Y, Harris KA, Shriver CD, Peoples GE, Ponniah S, Proc Amer Assoc Cancer Res, 1/1/2005
• Serum Cytokine Levels in Breast Cancer Patients Before and After Receiving a HER2/neu Vaccine Assessed Using Multiplex Technology.
  Dehqanzada ZA, Storrer CE, Hueman MT, Foley R, Harris KA, Jama Y, Shriver CD, Ponniah S, Peoples GE, Proc Amer Assoc Cancer Res, 1/1/2005
• Comparison of HLA-A2 Dimer and Tetramer Molecules for the Immunological Monitoring of Breast and Prostate Cancer Vaccine Clinical Trials.
  Hueman, MT (Primary Presenter), 10th National Symposium: Basic Aspects of Vaccines, Bethesda, MD, 1/29/2004
• Clinical Trial Results of Node Positive Breast Cancer Patients Receiving a HER2/neu (E75) Vaccine.
  Hueman, MT (Primary Presenter), 95th Annual Meeting of the American Association for Cancer Research, Orlando, FL, 1/28/2004
• Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High Risk Prostate Cancer Patients.
  Hueman, MT (Primary Presenter), 95th Annual Meeting of the American Association for Cancer Research, Orlando, FL, 1/28/2004
• Join now to see all

Lectures

• Neoplasm of the Pancreas: Diagnosis, Treatment and Prevention Among High-Risk Populations. 
  San Juan, Puerto Rico - 1/18/2015
• Current Surgical Management of Breast Cancer. 
  1/13/2015
• The Forward Surgical Team in Iraq and Afghanistan: Lessons Learned over Four Deployments. 
  Walter Reed National Military Medical Center, Bethesda, MD - 1/11/2015
• Surgical Management of Pancreatic Cancer. 
  1/3/2014
• Damage Control Resuscitation and Trauma Care in an Austere, Deployed Environment: The Afghanistan Forward Surgical Team Experience. 
  Johns Hopkins Hospital, Baltimore, MD - 1/23/2012
• Combat Trauma Care in an Austere, Deployed Environment: The Iraq and Afghanistan Forward Surgical Team Experience. 
  1/18/2010
• Multimodality Management of Gastrointestinal Stromal Tumor. 
  Bronx-Lebanon Hospital Center, Bronx, NY - 1/15/2010
• The Open Abdomen: Early Definitive Closure using the Serial Abdominal Closure Technique in Injured Operation Iraqi Freedom and Operation Enduring Freedom Soldiers. 
  Camp Victory, Baghdad, Iraq - 1/8/2007
• Immunophenotype Analysis of CD4, CD8, and Regulatory CD4+ CD25+ T cell Populations Induced by a HER2/neu Peptide (E75) Vaccine in Breast Cancer Patients. 
  Washington, DC - 1/4/2006
• Immunological Monitoring of Regulatory T Cells by Flow Cytometry in a novel HLA Class-II HER2/neu Peptide Vaccine Clinical Trial in Breast Cancer Patients. 
  Chicago, IL - 1/1/2006
• Immunophenotype Analysis of CD4 and CD8 T cell Populations Induced by a HER2/neu Peptide (E75) Vaccine in Breast Cancer Patients. 
  El Paso, TX - 1/25/2005
• Clinical Trial Results of a HER2/neu Peptide (E75) Vaccine in Preventing Recurrence in Node Positive Breast Cancer Patients. 
  Inova Fairfax Hospital, Falls Church, VA - 1/18/2005
• Comparison of Immunological Responses in Node-Positive and Node-Negative Breast Cancer Patients Receiving a HER2/neu (E75) Peptide Vaccine. 
  New York City, NY - 1/20/2004
• A More Sensitive Immunological Monitoring Tool for Cancer Vaccine Trials: A Direct Comparison of HLA-A2 Dimer and Tetramer Molecules in Measuring the In Vivo Immune Re... 
  New Orleans, LA - 1/13/2004
• The Effect of Changing Gamma Count Threshold on Sentinel Lymph Node Accuracy. 
  Augusta, GA - 1/13/2001
• Quantification of Regional Diastolic Function Through Application of the Regional Myocardial Pressure- Segment Length Relationship. 
  Duke University School of Medicine, Durham, NC - 1/7/1999
• Join now to see all